Bioversys Ag · SIX:BIOV
Bioversys — H1 2026 Earnings Presentation
21 slides from Bioversys's earnings presentation, Sep 9, 2026
Slide 1: Saving Lives in Resistant Times
Most Compelling Investment Opportunity in AMR space January 2023 SAVING LIVES IN RESISTANT TIMES Earnings call September 9, 2026 BIOVERSYS - PROPRIETARY MATERIAL 1
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation (the “Presentation”) has been prepared by BioVersys AG (“the Company” and together with its subsidiaries, “we”, “us” or the “Group”) solely for informational purposes. Certain statements in this Presentation are forward-looking statements, beliefs or opin
Slide 3: BioVersys Executive Team
BIOVERSYS EXECUTIVE TEAM Marc Gitzinger Hernan Levett Glenn E. Dale Daniel Ritz Chief Executive Officer, Chief Financial Officer Chief Development Officer Chief Scientific Officer Founder 30+ years finance and management 30+ years research and development 30+ years research and development 15+ years
Slide 4: Innovative, Diverse and De-risked Pipeline
INNOVATIVE, DIVERSE AND DE-RISKED PIPELINE Next-Generation Antimicrobial Drugs, Two Proprietary Platforms Expected Key Commercial Program Indication R&D/Preclinical Phase 1 Phase 2 Phase 3 Potential Catalyst Rights Hospital infections $800m in Expected BV100 Phase 3 trial (RIV-TARGET) FPFV: April 20
Slide 5: Key Highlights
KEY HIGHLIGHTS A strong half-year focused on execution and disciplined capital allocation BV100 PHASE 3 Alpibectir PHASE 2 Carbapenem-resistant Acinetobacter baumannii infections Multi-drug resistant pulmonary and meningeal tuberculosis › First-patient-first-visit reported in RIV-TARGET (April 2026)
Slide 6: Pull Incentives Worldwide
PULL INCENTIVES WORLDWIDE Progress update. Source: BEAM Alliance Implemented € € € € UK Subscription German high-price Italian secured Swedish revenue guarantee model model reimbursement model Up to £23.7m/year subscription « Reserve antibiotic » status AWaRe/BPPL antibiotics are Only intended to gu
Slide 7: BV100: Severe hospital infections caused by carbapenem resistant Acinetobacter baumannii
BV100: Severe hospital infections caused by carbapenem resistant Acinetobacter baumannii
Slide 8: BV100 development strategy
BV100 development strategy Our key focus areas in 2026-2027 are to progress clinical trials Phase 3 and Phase 2b to support regulatory submissions and commercial adoption of BV100 Phase 3 Global registrational programme Phase 2b Real world evidence programme • Trial aimed to seek initial regulatory
Slide 9: BV100 Outlook
BV100 OUTLOOK All focus on clinical trial execution Phase 3 Global registrational programme Phase 2b Real world evidence programme • Study initiated recruiting, with first drug safety monitoring board • Open-label trial is scheduled to initiate first sites in September in update anticipated for late
Slide 10: Alpibectir: Pulmonary and meningeal Tuberculosis
Alpibectir: Pulmonary and meningeal Tuberculosis
Slide 11: Alpibectir Clinical Development
ALPIBECTIR CLINICAL DEVELOPMENT Identifying future high impact regimens for Tuberculosis patients TB Meningitis Pulmonary TB • Clinical trial consortium for Phase 2 TB meningitis trial established • UNITE4TB Step 2c trial (Phase 2b) reported FPFV in March 2026, slightly ahead of our original guidanc
Slide 12: Financial Highlights
VERSYS Financial Highlights
Slide 13: H1 2026 Highlights
H1 2026 HIGHLIGHTS • Cash and Cash equivalents at 30 June 2026 amounted to CHF 69.3 million. • The successful initiation of the pivotal Phase 3 RIV-TARGET trial for BV100, marked by first patient first visit in April 2026, contributed to an increase in R&D expenses to CHF 13.6 million for the first
Slide 14: Profit and Loss – 30 June 2026
PROFIT AND LOSS – 30 JUNE 2026 in CHF million (based on consolidated IFRS financial statements) Results HY1 2026 Change vs HY1 2025 2,0 1,4 -13,6 -7,3 -3,0 0,0 -1,0 0,0 0,6 -4,6 -15,6 0,7 Operating R&D G&A Finance Income tax Net loss for Operating R&D G&A Finance Income tax Net loss for income expen
Slide 15: Balance Sheet – 30 June 2026
BALANCE SHEET – 30 JUNE 2026 in CHF million (based on consolidated IFRS financial statements) Financial Position as of June 30, 2026 Change vs June 30, 2025 76,9 76,9 0,2 9,7 22,4 44,8 -13,9 76,0 -13,7 0,5 0,8 -13,7 0,9 -15,0 Non- Current Total Equity Non- Current Total Non- Current Total Equity Non
Slide 16: Cash Flow – 30 June 2026
CASH FLOW – 30 JUNE 2026 in CHF million (based on consolidated IFRS financial statements) Cash Flow 82,5 -13,0 69,3 -0,3 -0,1 0,2 Cash and cash Cash flow from Cash flow from Cash flow from Exchange Cash and cash equivalents 31 Dec 2025 operating activities investing activities financing activities d
Slide 17: Guidance Operating Result for the Year 2026
GUIDANCE OPERATING RESULT FOR THE YEAR 2026 Improved operating loss guidance for the year 2026, expected to be in the range of CHF 32 to 34 million in CHF million +8,0 0,6 0,5 3,1 -32,0 3,3 -34,0 0,5 -40,0 -45,0 Higher end Lower end Revenue & lower Pass- Phasing Other G&A Lower end Higher end Guidan
Slide 18: Guidance Cash at Yearend 2026
GUIDANCE CASH AT YEAREND 2026 Improved cash and cash equivalents guidance for yearend 2026, expected to be in the order of CHF 53 million in CHF million +10,0 53,0 0,5 2,4 3,1 0,6 43,0 3,3 0,2 Guidance Cash Revenue & lower Pass- Phasing Other G&A Working Guidance Cash at yearend 2026 other income th
Slide 19: Guidance for 2026
GUIDANCE FOR 2026 • Operating Loss for the year 2026 expected to be in the range of CHF 32 to 34 million • Cash and cash equivalents at yearend are estimated to be in the order of CHF 53 million • We expect the company’s operations to be funded into 2028 • Advance discussions with key institutions r
Slide 20: Focused on Shareholder Value Creation
FOCUSED ON SHAREHOLDER VALUE CREATION Achievements H1 2026 ✓ Fast Track Designation for BV100 from the US FDA ✓ BV100 RIV-TARGET is actively recruiting; Completed BV100 Phase 1 bridging study in China; Completed another Phase 1 DDI study for BV100 in combination with low dose Polymyxin B. ✓ BV-100 R
Slide 21: Q&A Contact information
Q&A Contact information: Website: www.bioversys.com IR mail: IR@bioversys.com